Using new wearable technology to monitor Niemann-Pick disease

22 Mar 2016, 4:15 p.m.

Two balls, one orange and red and the other purple, yellow, red and green with 'physio' written across it in black.

A smartphone app, combined with wearable technology, will allow doctors to remotely monitor patients with conditions that limit their ability to voluntarily move their muscles. The app, known as 'aparito', uses a motion-tracking writsband to record the movements of patients with ataxia, and other related ambulatory conditions.

The data from the tracker is sent via a smartphone app, where it can be combined with other information such as medication adherence and events such as falls or seizures. Healthcare professionals can have constant access to this information via the web.

Great Ormond Street BRC-researcher Professor Paul Gissen, has been working closely with aparito, and Great Ormond Street Hospital is to be the first in the UK to use this new wearable technology in clinical practice. Patients could receive fewer tests and have shorter hospital visits by using the app, which will monitor routine activity in a continuous, non-invasive way.

Researchers funded to cure inflammatory disease

Researchers from University College London (UCL) and Great Ormond Street Hospital (GOSH) will join researchers across the UK and international partners in a bid to transform how chronic inflammatory disease is treated.

Innovative imaging project aims to save children’s sight

Researchers from GOSH and UCL are leading a project that could transform how children at risk of sight loss are monitored, by adapting advanced eye imaging technology for use closer to home

Five GOSH clinicians recognised with professorial appointments at UCL

Five clinician researchers from GOSH have been promoted to professor by University College London (UCL), recognising their outstanding contributions to research, innovation and child health.

From staff idea to global innovation: Taking the next step towards improving patient safety

A simple idea developed by a GOSH clinician has secured a commercial partner.